Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05281692 · ClinicalTrials.gov registry record
Comparison of EPM-IX to Currently Used Specimen Transportation and Extraction Devices ( CGI-EPM-IX )
A clinical trial of SARS-CoV-2, sponsored by Convergent Genomics.
- Completed
- Registry status
- 205
- Enrollment target
- 1
- Study location
NCT05281692: Completed study of SARS-CoV-2, sponsored by Convergent Genomics.
NCT05281692 is a study of SARS-CoV-2 that has completed, run by Convergent Genomics. The registered enrollment target is 205 participants, below the 3,448-participant average among 34 other SARS-CoV-2 trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05281692, a study of SARS-CoV-2, has completed, sponsored by Convergent Genomics.
- COMPLETED
- Registry status
- 205 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a research study to evaluate the clinical utility of the Enhanced Preservation Media with Integrated Extraction (EPM-IX)
Primary Outcome
Comparison of diagnostic performances (sensitivity, specificity, and predictive values) of EPM-IX vs Med Schenker's STM viral media with detection of SARS-CoV-2 infection.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Enhanced Preservation Media (EPM-IX)
Study Locations (1)
Illinois
- UroPartners Urology Group - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2022-02-02 |
| Est. Completion | 2022-03-21 |
What the finished NCT05281692 record still lists
NCT05281692 is an observational study that tracks outcomes without assigning an intervention. The registered 205 participants enrollment target is mid-sized for trials with a published cap, below the 3,448-participant average among 34 other SARS-CoV-2 trials with a reported enrollment target (94% lower).
The record links to 1 condition, with SARS-CoV-2 appearing as the primary indexed condition, and to 1 intervention - of which Enhanced Preservation Media (EPM-IX) is the first listed.
NCT05281692 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT05281692 about?
NCT05281692 is a clinical study titled "Comparison of EPM-IX to Currently Used Specimen Transportation and Extraction Devices ( CGI-EPM-IX )". This is a research study to evaluate the clinical utility of the Enhanced Preservation Media with Integrated Extraction (EPM-IX)
What is the current status of trial NCT05281692?
This trial is currently completed. The enrollment target is 205 participants. The study started on 2022-02-02. Estimated completion is 2022-03-21.
What conditions does trial NCT05281692 study?
This clinical trial studies the following conditions: SARS-CoV-2.
What interventions are being tested in trial NCT05281692?
The interventions under investigation include: Enhanced Preservation Media (EPM-IX) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05281692?
This trial is sponsored by Convergent Genomics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05281692 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for SARS-CoV-2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05281692's enrollment target sits among peer trials
205 20th of 34 higher than 15 of 34 other SARS-CoV-2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other SARS-CoV-2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
RECRUITING · Phase 4
-
Improving the Collaborative Health of Minority COVID-19 Survivor and Carepartner Dyads
RECRUITING · NA
-
Determinants of SARS (Severe Acute Respiratory Syndrome)-COV2 (COVID-19) Persistence After Convalescence
RECRUITING
-
Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease
RECRUITING · Phase 1
-
Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03457493 · 205 participants · Phase 1
The University of Alabama At Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy
- NCT05134857 · 205 participants · Phase 2
The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study
- NCT05181891 · 205 participants · Phase 2
Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking
- NCT05283811 · 205 participants · NA
Understanding Prefrontal and Medial Temporal Neuronal Responses to Algorithmic Cognitive Variables in Epilepsy Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI